Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 121

Sort by

Sort Order Select

Journal Articles

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Maria Lia Palomba, MD, Leo I. Gordon, MD, Tanya Siddiqi, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Jon E. Arnason, MD, Nilanjan Ghosh, MD PhD, Amitkumar Mehta, MD, Scott R. Solomon, MD, Thalia Farazi, MD PhD, Jacob Garcia, MD, Christine Dehner, BSc, Ken Ogasawara, PhD MPH, Jie Gao, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136158

Published: 2020

Journal Articles

Patient-Reported Outcomes at Time of CAR-T Cell Therapy

Erin Mullane, Taylor Jones, Jenna Voutsinas, MPH, Qian Vicky Wu, PhD, Elizabeth Loggers, MD PhD, Jesse Fann, David G. Maloney, MD PhD, Merav Bar

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-134646

Published: 2020

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

David G. Maloney, MD PhD, John Kuruvilla, MD, Christopher P Fox, MD PhD, Guillaume Cartron, MD PhD, Daniel Li, PhD, Jens Hasskarl, MD, Ashley Bonner, PhD, Yixie Zhang, PhD, Fei Fei Liu, BSc, MBA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137719

Published: 2020

Journal Articles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136219

Published: 2020

Journal Articles

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Lorena Panaite, MBBS, Jordan Gauthier, MD, Paula Perkins, MS,PA-C, Jenna Voutsinas, MPH, Qian Vicky Wu, PhD, Angela Kirk, PA-C, Aisling Cearley, PA-C, Erin Mullane, DNP, Ryan D. Cassaday, MD, Hans-Peter Kiem, MDPhD, Victor A. Chow, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Mazyar Shadman, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134816

Published: 2020

Journal Articles

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

Julio C. Chavez, MD, Caron A. Jacobson, MD, Alison R. Sehgal, MD, Sattva S. Neelapu, MD, David G. Maloney, MD PhD, Gilles Salles, MD PhD, Basem M. William, MDMRCP, Yin Yang, MS, Lovely Goyal, PhD, Justin Chou, PhD, Vicki Plaks, LLB, PhD, Mauro P. Avanzi, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-135871

Published: 2020

Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136136

Published: 2020

Journal Articles

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Jordan Gauthier, MD MSc, Cassie Chou, MDPhD, Alexandre V. Hirayama, MD, Salvatore Fiorenza, MBBS, PhD, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Tinh-Doan Phi, BSc, Rachel Steinmetz, BSc, Abby Jamieson, BSc, Delaney R Kirchmeier, BSc, Henna N Di, BSc, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140120

Published: 2020

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Damian J. Green, MD, Margot Pont, PhD, Andrew J. Cowan, MD, Gabriel O Cole, Blythe Duke Sather, PhD, Anne M Nagengast, RN, Xaoling Song, Sushma Thomas, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2019) 134 (Supplement_1): 1856.

https://doi.org/10.1182/blood-2019-129582

Published: 2019

Journal Articles

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 2889.

https://doi.org/10.1182/blood-2019-124962

Published: 2019

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Brian Kornblit, MD PhD, Barry Storer, Michael B. Maris, MD, Niels Smedegaard Andersen, MD PhD, Thomas R. Chauncey, MD PhD, Effie W. Petersdorf, MD, Ann Woolfrey, MD, David G. Maloney, MD PhD, Rainer Storb, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 369.

https://doi.org/10.1182/blood-2019-123196

Published: 2019

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, Jacob Garcia, MD, Christine Dehner, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 66.

https://doi.org/10.1182/blood-2019-127145

Published: 2019

Journal Articles

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Merav Bar, MD, Julia Ruark, MD MPH, Erin Mullane, DNP, Nancy Cleary, BSc, Ana Cordeiro, MD, Evandro D. Bezerra, MD, Jenna M. Voutsinas, MPH, Bronwen E. Shaw, MD PhD, Qian Vicky Wu, PhD, Kathryn E Flynn, PhD, Stephanie J. Lee, MD MPH, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Jesse Fann

Blood (2019) 134 (Supplement_1): 4453.

https://doi.org/10.1182/blood-2019-122755

Published: 2019

Journal Articles

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

David G. Maloney, MD PhD, Fei Fei Liu, Lisette Nientker, Cathelijne Alleman, Brian Hutton, PhD, Jacob Garcia, MD

Blood (2019) 134 (Supplement_1): 5821.

https://doi.org/10.1182/blood-2019-127664

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

NARROW

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Patient-Reported Outcomes at Time of CAR-T Cell Therapy

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only